High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

The board of Sage Therapeutics unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company. That's not surprising – Sage filed a ...

TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

US-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an ...

Sage Therapeutics (SAGE) announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the ...

The "43rd Annual JP Morgan Healthcare Conference, January 13-16, 2025" report has been added to ResearchAndMarkets.com's offering.The 43rd Annual JP Morgan Healthcare Conference took place in San ...

Biogen Pharmachem Industries Ltd share price was down by -2.91% from the previous closing price of ₹1.03. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

After hours: 7:45:25 p.m. EST ...